CRDL.TO
Cardiol Therapeutics Inc.
TorontoCADEQUITY
Healthcare
DELAYED
Last price
2.58
▼ 0.03 (1.15%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.63
Prev close
2.61
Day high
2.63
Day low
2.56
Volume
144.87K
Market cap
$301.40M
P/E (TTM)
—
52W range
1.23 – 2.75
Day trading desk
Gap from prior close
+0.77%
Prior close 2.61
VWAP
2.58
-0.08% from price
Relative volume
2.64×
Unusually busy
Session range
2.73%
2.56 – 2.63
Position in range
29%
Near session low
ATR (14D)
0.16
6.30% of price
Prior day high
2.75
PDH
Prior day low
2.53
PDL
Bid / ask spread
—
Quote not published
Session volume
280.33K
Avg 106.22K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.79%
+4.2%
1M
+41.76%
+38.0%
3M
+41.76%
+38.7%
6M
+85.61%
+74.5%
YTD
+96.95%
+84.7%
1Y
+61.25%
+41.3%
3Y
+111.48%
+37.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRDL.TO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.77M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 17, 25 | Elsley (David) Director of Issuer |
BUY | 100.00K | $100.00K | Direct |
| Oct 17, 25 | Torreamione (Guilermo) Senior Officer of Issuer |
BUY | 50.00K | $50.00K | Direct |
| Oct 1, 25 | Hamer (Andrew Warwick M.D.) Senior Officer of Issuer |
— | 133.33K | — | Direct |
| Sep 8, 25 | Chao (Jennifer M) Director of Issuer |
— | 13.33K | — | Direct |
| Sep 8, 25 | Hamer (Andrew Warwick M.D.) Senior Officer of Issuer |
— | 70.00K | — | Direct |
| Sep 8, 25 | Loxam (Teri) Director of Issuer |
— | 13.33K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Chao (Jennifer M) |
Director of Issuer | 133.33K | Exercise of rights |
Elsley (David) |
Director of Issuer | 1.34M | Acquisition or disposition carried out privately |
Hamer (Andrew Warwick M.D.) |
Senior Officer of Issuer | 669.95K | Exercise of rights |
Loxam (Teri) |
Director of Issuer | 133.33K | Exercise of rights |
Torreamione (Guilermo) |
Senior Officer of Issuer | 309.31K | Acquisition or disposition carried out privately |
Fundamentals
Market cap$301.40M
Enterprise value$275.43M
Revenue (TTM)—
Gross profit—
EBITDA$-35.85M
Net income$-34.08M
EPS (TTM)$-0.34
Free cash flow$-15.48M
Total cash$26.08M
Total debt$107.00K
Book value / share$0.21
Shares outstanding116.82M
Float92.10M
Short % of float0.31%
Dividend yield—
Beta (5Y)0.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.51
PEG ratio—
Price / sales—
Price / book12.46
EV / revenue—
EV / EBITDA-7.68
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-190.18%
Return on assets-90.92%
Debt / equity0.45
Current ratio5.55
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $14.02M | $14.01M | $14.22M | $18.96M | +0.0% |
| Selling, general & admin | $20.20M | $25.89M | $15.56M | $22.37M | -22.0% |
| Total operating expense | $34.32M | $40.28M | $29.79M | $41.34M | -14.8% |
| Operating income | -$34.32M | -$40.28M | -$29.79M | -$41.34M | +14.8% |
| Net interest income | $726.40K | $1.19M | $2.04M | $1.24M | -39.1% |
| Pre-tax income | -$33.82M | -$36.68M | -$28.13M | -$30.93M | +7.8% |
| Net income | -$33.82M | -$36.68M | -$28.13M | -$30.93M | +7.8% |
| Net income to common | -$33.82M | -$36.68M | -$28.13M | -$30.93M | +7.8% |
| Basic EPS | -0.39 | -0.51 | -0.44 | -0.49 | +23.5% |
| Diluted EPS | -0.39 | -0.51 | -0.44 | -0.49 | +23.5% |
| EBIT | -$34.32M | -$40.28M | -$29.79M | -$41.34M | +14.8% |
| EBITDA | -$34.21M | -$39.90M | -$29.54M | -$41.12M | +14.3% |
| Basic shares | 86.99M | 71.57M | 64.46M | 62.51M | +21.5% |
| Diluted shares | 86.99M | 71.57M | 64.46M | 62.51M | +21.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.42M | $30.58M | $34.93M | $59.47M | — | -30.0% |
| Cash & short-term investments | $21.42M | $30.58M | $34.93M | $59.47M | — | -30.0% |
| Accounts receivable | $55.73K | $100.37K | $142.75K | $209.92K | — | -44.5% |
| Total current assets | $23.50M | $31.67M | $36.15M | $61.44M | — | -25.8% |
| Property, plant & equipment | $118.09K | $195.59K | $337.06K | $295.74K | — | -39.6% |
| Goodwill & intangibles | — | $0 | $210.36K | $294.80K | $379.25K | — |
| Total assets | $23.62M | $31.86M | $36.70M | $62.03M | — | -25.9% |
| Total current liabilities | $5.66M | $7.01M | $8.30M | $9.80M | — | -19.3% |
| Total debt | $125.52K | $158.53K | $174.34K | $72.87K | — | -20.8% |
| Total liabilities | $5.74M | $7.14M | $8.45M | $9.83M | — | -19.5% |
| Retained earnings | -$213.07M | -$179.25M | -$142.58M | -$114.45M | — | -18.9% |
| Shareholder equity | $17.88M | $24.73M | $28.25M | $52.20M | — | -27.7% |
| Working capital | $17.85M | $24.66M | $27.86M | $51.63M | — | -27.6% |
| Net tangible assets | $17.88M | $24.73M | $28.04M | $51.91M | — | -27.7% |
| Shares issued | 100.26M | 82.61M | 65.35M | 64.04M | — | +21.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$33.82M | -$36.68M | -$28.13M | -$30.93M | +7.8% |
| Depreciation & amortisation | $101.98K | $373.11K | $248.35K | $219.91K | -72.7% |
| Stock-based compensation | $10.70M | $14.28M | $4.16M | $5.01M | -25.1% |
| Change in working capital | -$733.34K | -$931.57K | -$545.88K | $5.75M | +21.3% |
| Operating cash flow | -$23.85M | -$25.06M | -$25.18M | -$27.22M | +4.8% |
| Capital expenditure | -$24.48K | -$21.29K | -$64.31K | -$74.71K | -15.0% |
| Investing cash flow | -$24.48K | -$21.29K | -$64.31K | -$74.71K | -15.0% |
| Financing cash flow | $15.54M | $18.84M | -$55.38K | -$53.93K | -17.5% |
| Free cash flow | -$23.88M | -$25.08M | -$25.24M | -$27.30M | +4.8% |
| End cash position | $21.42M | $30.58M | $34.93M | $59.47M | -30.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $4.95M | $2.74M | $4.79M | $2.73M | $3.76M | +80.5% |
| Selling, general & admin | $4.73M | $5.26M | $5.37M | $4.92M | $4.65M | -10.1% |
| Total operating expense | $9.71M | $8.03M | $10.18M | $7.68M | $8.43M | +20.9% |
| Operating income | -$9.71M | -$8.03M | -$10.18M | -$7.68M | -$8.43M | -20.9% |
| Net interest income | $200.72K | $175.21K | $122.26K | $180.67K | $248.27K | +14.6% |
| Pre-tax income | -$10.82M | -$7.21M | -$9.96M | -$8.35M | -$8.29M | -50.0% |
| Net income | -$10.82M | -$7.21M | -$9.96M | -$8.35M | -$8.29M | -50.0% |
| Net income to common | -$10.82M | -$7.21M | -$9.96M | -$8.35M | -$8.29M | -50.0% |
| Basic EPS | -0.10 | — | -0.12 | -0.10 | -0.10 | — |
| Diluted EPS | -0.10 | — | -0.12 | -0.10 | -0.10 | — |
| EBIT | -$9.71M | -$8.03M | -$10.18M | -$7.68M | -$8.43M | -20.9% |
| EBITDA | -$9.68M | -$8.00M | -$10.15M | -$7.65M | -$8.40M | -20.9% |
| Basic shares | 108.99M | — | 84.73M | 82.65M | 82.61M | — |
| Diluted shares | 108.99M | — | 84.73M | 82.65M | 82.61M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27.67M | $21.42M | $11.62M | $18.20M | $23.29M | — | +29.2% |
| Cash & short-term investments | $27.67M | $21.42M | $11.62M | $18.20M | $23.29M | — | +29.2% |
| Accounts receivable | $70.08K | $55.73K | $37.49K | $58.92K | $75.96K | — | +25.7% |
| Total current assets | $31.27M | $23.50M | $12.81M | $19.77M | $25.27M | — | +33.0% |
| Property, plant & equipment | $138.97K | $118.09K | $140.98K | $163.51K | $182.54K | — | +17.7% |
| Goodwill & intangibles | — | — | — | — | — | $0 | — |
| Total assets | $31.41M | $23.62M | $12.95M | $19.94M | $25.45M | — | +33.0% |
| Total current liabilities | $7.13M | $5.66M | $3.29M | $8.02M | $7.75M | — | +26.0% |
| Total debt | $116.41K | $125.52K | $134.20K | $142.55K | $150.66K | — | -7.3% |
| Total liabilities | $7.20M | $5.74M | $3.39M | $8.13M | $7.87M | — | +25.4% |
| Retained earnings | -$223.89M | -$213.07M | -$205.90M | -$195.90M | -$187.54M | — | -5.1% |
| Shareholder equity | $24.20M | $17.88M | $9.56M | $11.81M | $17.59M | — | +35.4% |
| Working capital | $24.14M | $17.85M | $9.52M | $11.75M | $17.52M | — | +35.3% |
| Net tangible assets | $24.20M | $17.88M | $9.56M | $11.81M | $17.59M | — | +35.4% |
| Shares issued | 111.87M | 100.26M | 87.46M | 82.67M | 82.61M | — | +11.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.82M | -$7.21M | -$9.96M | -$8.35M | -$8.29M | -50.0% |
| Depreciation & amortisation | $26.71K | $25.98K | $25.55K | $25.47K | $24.99K | +2.8% |
| Stock-based compensation | $1.84M | $3.01M | $4.00M | $2.54M | $1.15M | -38.9% |
| Change in working capital | $119.11K | -$630.72K | -$622.15K | $671.36K | -$151.82K | +118.9% |
| Operating cash flow | -$7.52M | -$5.23M | -$6.93M | -$4.55M | -$7.15M | -43.9% |
| Capital expenditure | -$47.59K | -$3.09K | -$3.02K | -$6.44K | -$11.94K | -1,441.0% |
| Investing cash flow | -$47.59K | -$3.09K | -$3.02K | -$6.44K | -$11.94K | -1,441.0% |
| Financing cash flow | $13.60M | $15.55M | -$13.84K | $20.42K | -$13.84K | -12.5% |
| Free cash flow | -$7.57M | -$5.23M | -$6.93M | -$4.56M | -$7.17M | -44.7% |
| End cash position | $27.67M | $21.42M | $11.62M | $18.20M | $23.29M | +29.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.10 | -0.05 | +48.3% |
| Mar 2026 | -0.09 | -0.10 | -11.1% |
| Dec 2025 | -0.11 | -0.07 | +36.4% |
| Sep 2025 | -0.11 | -0.12 | -14.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.08 | 2 | $0 | 0.0% |
| Next quarter | -0.09 | 2 | $0 | 0.0% |
| Current year | -0.33 | 2 | $0 | 0.0% |
| Next year | -0.30 | 3 | $1.18M | 0.0% |
Analyst targets & ownership
Mean target$6.00
High target$7.00
Low target$5.00
Implied upside132.56%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders2.37%
Held by institutions25.91%
Institutions holding59
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.42
+6.57% from price
SMA 20
2.10
+22.68% from price
SMA 50
1.77
+45.61% from price
SMA 100
1.80
+43.44% from price
SMA 200
1.60
+60.94% from price
EMA 12
2.38
+8.61% from price
EMA 26
2.12
+21.69% from price
EMA 50
1.93
+33.60% from price
RSI (14)
75.6
Overbought
MACD (12,26,9)
0.26
Hist 0.05
ATR (14)
0.16
6.30% of price
Realised vol 30D
68.4%
Annualised
Bollinger upper
2.84
20, 2σ
Bollinger lower
1.37
20, 2σ
50 / 200 cross
Golden
1.77 vs 1.60
Trend bias
Above 200
+60.94%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.85
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
68.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.4%
Peak to trough
Max drawdown 5Y
-89.6%
Peak to trough
ATR 14
0.16
6.30% of price
Beta (reported)
0.47
5Y monthly, from filing
Short interest
Shares short
354.08K
Prior 196.58K
Change vs prior
+80.1%
Shorts adding
% of float
0.31%
Normal
% of shares out
0.30%
Against total outstanding
Days to cover
2.0
Liquid
Float
92.10M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 1, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 2, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| Apr 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 7, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 24, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 18, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 24, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Headlines
What Does a D-Wave Quantum Insider's Sale of 23,850 Shares Mean for Investors?
Motley Fool · 16m ago
Thousands expected at Sweden climate demo as election looms
AFP · 17m ago
Cowboys vs. Cardinals highlights Preseason Week 2
NFL Highlights · 20m ago
Which Energy ETF Is a Better Buy: Broad Vanguard Fund or Concentrated XLE?
Motley Fool · 23m ago
Joe Milton III's best plays from 3-TD game vs. Cardinals Preseason Week 2
NFL Highlights · 31m ago
BioNTech (BNTX) Is Up 25.2% After First-in-Class Pumitamig Plus B7H3 ADC Lung Data – What's Changed
Simply Wall St. · 37m ago
Applied Industrial Technologies (AIT) Could Be 15% Undervalued After Earnings And 2027 Guidance
Simply Wall St. · 37m ago
Everpure (P) Lands Supply Agreement With A Second Top Five Hyperscaler
Simply Wall St. · 37m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.